Beam Therapeutics (BEAM) Operating Margin (2019 - 2025)
Historic Operating Margin for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to 1307.6%.
- Beam Therapeutics' Operating Margin fell 5612000.0% to 1307.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 837.12%, marking a year-over-year decrease of 7848800.0%. This contributed to the annual value of 654.25% for FY2024, which is 6075300.0% down from last year.
- Beam Therapeutics' Operating Margin amounted to 1307.6% in Q3 2025, which was down 5612000.0% from 1419.22% recorded in Q2 2025.
- In the past 5 years, Beam Therapeutics' Operating Margin ranged from a high of 42.02% in Q4 2023 and a low of 3339550.0% during Q1 2021
- Moreover, its 5-year median value for Operating Margin was 746.4% (2024), whereas its average is 228595.9%.
- Per our database at Business Quant, Beam Therapeutics' Operating Margin tumbled by 2000000000bps in 2021 and then skyrocketed by 2000000000bps in 2022.
- Over the past 5 years, Beam Therapeutics' Operating Margin (Quarter) stood at 124.31% in 2021, then crashed by -257bps to 444.1% in 2022, then skyrocketed by 109bps to 42.02% in 2023, then plummeted by -892bps to 332.71% in 2024, then plummeted by -293bps to 1307.6% in 2025.
- Its last three reported values are 1307.6% in Q3 2025, 1419.22% for Q2 2025, and 1596.87% during Q1 2025.